EUREPA MF

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for **EUREPA MF** [repaglinide 1mg and metformin 500mg Tablets and repaglinide 2mg and metformin 500mg Tablets] [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: **Repaglinide** lowers blood glucose levels by stimulating the release of insulin from the pancreas. Repaglinide closes ATP-dependent potassium channels in the beta cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the beta-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. **Metformin** is an anti-hyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes by lowering both the basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

INDICATION: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a meglitinide and metformin hydrochloride or who have inadequate glycemic control on a meglitinide alone or metformin hydrochloride alone.

DOSAGE AND ADMINISTRATION: Repaglinide and metformin hydrochloride tablet can be administered 2 to 3 times a day up to a maximum daily dose of 10mg repaglinide/2500 mg metformin hydrochloride. No more than 4mg repaglinide/1000mg metformin hydrochloride should be taken per meal. Patients who skip a meal should be instructed to skip the repaglinide and metformin hydrochloride tablet dose for that meal.

CONTRAINDICATION: Contraindicated in patients with renal impairment, acute or chronic metabolic acidosis, diabetic ketoacidosis, gemfibrozil and itraconazole, known hypersensitivity to repaglinide, metformin hydrochloride or any inactive ingredients.

WARNINGS & PRECAUTIONS: Use cautiously or stop the Eurepa MF in patient with lactic acidosis, impairment of renal function, radiologic studies with intravascular iodinated contrast materials, impaired hepatic function, alcohol intake, combination with NPH-insulin, gemfibrozil, hypoglycemia, vitamin b_{12} levels, surgical procedures, loss of control of blood glucose, use of concomitant medications affecting renal function or metformin disposition, hypoxic states, change in clinical status of patients with previously controlled type 2 diabetes and pregnancy.

DRUG INTERACTIONS: Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin), gemfibrozil, trimethoprim, itraconazole, ketoconazole and rifampin.

ADVERSE REACTIONS: Diarrhea, nausea, vomiting, hypoglycemia, headache, upper respiratory tract infection, alopecia, hemolytic anemia, pancreatitis, stevens-johnson syndrome, severe hepatic dysfunction including jaundice and hepatitis, hypertension, abnormal electrocardiogram, myocardial infarction, arrhythmias and palpitations.

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/EUREPA MF 1,2, 500mg/Aug-2015/01/ABPI

(Additional information is available on request)